Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.54 |
| ▸ | PSEN2 | P49810 | 12/20 | 0.54 |
| ▸ | APH1B | Q8WW43 | 12/20 | 0.54 |
| ▸ | NCSTN | Q92542 | 12/20 | 0.54 |
| ▸ | APH1A | Q96BI3 | 12/20 | 0.54 |
| ▸ | PSENEN | Q9NZ42 | 12/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041934 | 1.00 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12957546 | 0.96 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8209762 | 0.89 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12957521 | 0.86 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1040854 | 0.83 | PSEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8206040 | 0.81 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1039991 | 0.81 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13512574 | 0.78 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12957548 | 0.78 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13513973 | 0.74 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010041-A1 | DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| WO-2008030391-A2 | DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010041-A1 | DIFLUORINATED PIPERIDINES FOR TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | PSEN1, PSEN2, BACE1 | PSEN1 1/4885PSEN2 2/4885APH1B 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.